Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate.

nemorubicin (PNU 152243) - Nerviano Medical Sciences

Anktiva (nogapendekin alfa inbakicept-pmln) - ImmunityBio

aldoxorubicin (INNO-206) - LadRx

PD-L1.t-haNK - ImmunityBio

http://www.ncbi.nlm.nih.gov/pubmed/39373598

Chaitali Nangia; Himanshu Brahmbhatt; Jennifer MacDiarmid; Katayoun Moini; Lennie Sender; Patricia Spilman; Patrick Soon-Shiong; Tara Seery

Oct 7, 2024